DV Trading LLC Invests $5.36 Million in Minerva Neurosciences, Inc $NERV

DV Trading LLC purchased a new stake in shares of Minerva Neurosciences, Inc (NASDAQ:NERV) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 889,254 shares of the biopharmaceutical company’s stock, valued at approximately $5,358,000. Minerva Neurosciences comprises approximately 0.1% of DV Trading LLC’s holdings, making the stock its 10th biggest position.

Several other large investors have also made changes to their positions in the company. Spruce Street Capital LP bought a new position in Minerva Neurosciences during the fourth quarter valued at approximately $6,655,000. Federated Hermes Inc. grew its position in Minerva Neurosciences by 297.5% in the fourth quarter. Federated Hermes Inc. now owns 5,371,775 shares of the biopharmaceutical company’s stock worth $21,595,000 after acquiring an additional 4,020,500 shares in the last quarter. Logos Global Management LP bought a new stake in Minerva Neurosciences in the fourth quarter worth approximately $13,310,000. Adage Capital Partners GP L.L.C. acquired a new position in shares of Minerva Neurosciences during the 4th quarter worth $11,409,000. Finally, Farallon Capital Management LLC acquired a new position in shares of Minerva Neurosciences during the 4th quarter worth $9,507,000. Institutional investors own 34.56% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Citizens Jmp assumed coverage on shares of Minerva Neurosciences in a research note on Wednesday, April 15th. They issued a “market outperform” rating and a $14.00 price objective for the company. Wall Street Zen lowered Minerva Neurosciences from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Minerva Neurosciences in a research report on Wednesday, June 24th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $10.50.

Minerva Neurosciences Stock Down 1.0%

Shares of NASDAQ:NERV opened at $3.98 on Friday. The company has a market cap of $185.43 million, a price-to-earnings ratio of -0.14 and a beta of -0.16. The business has a 50 day moving average price of $4.60 and a 200 day moving average price of $5.42. Minerva Neurosciences, Inc has a twelve month low of $1.76 and a twelve month high of $12.46.

Minerva Neurosciences (NASDAQ:NERV) last issued its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.04). Analysts anticipate that Minerva Neurosciences, Inc will post -0.2 EPS for the current year.

Minerva Neurosciences Profile

Minerva Neurosciences, Inc is a clinical?stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The company’s research and development efforts are directed toward addressing unmet needs in psychiatric and neurological conditions, leveraging its expertise in neuropharmacology and receptor modulation. Minerva’s goal is to bring forward differentiated molecules that can offer improved efficacy and safety profiles compared to existing treatments.

The company’s most advanced programs include roluperidone (formerly MIN-101), which has been investigated for the treatment of negative symptoms of schizophrenia, and MIN-117, a novel serotonergic agent being evaluated in major depressive disorder.